financetom
Business
financetom
/
Business
/
GRSE signs pact with Rolls Royce Solutions to manufacture marine diesel engines
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GRSE signs pact with Rolls Royce Solutions to manufacture marine diesel engines
Jan 28, 2023 9:47 AM

Defence PSU Garden Reach Shipbuilders and Engineers (GRSE) Ltd has signed a memorandum of understanding (MoU) with Rolls Royce Solutions of Germany for manufacture of high-quality marine diesel engines at the former’s plant in Ranchi, an official said here on Saturday.

Share Market Live

NSE

The Indian Navy’s Chief of Material Vice Admiral Sandeep Naithani was present at the signing of the MoU, he said.

"The MoU deals with transfer of technology related to engine assembly, painting, parts sourcing and after-sales service for these engines that are to be assembled at GRSE’s Diesel Engine Plant in Ranchi," the company official said in a statement.

Also Read: Rolls Royce reports highest sales in 118 years

It will provide a great opportunity to local industry, particularly micro, small and medium enterprises involved in the manufacture of components and spares, he said.

"Under the agreement, GRSE and Rolls Royce Solutions will co-operate in the licence production and localisation of the technologically advanced MTU S4000 governmental marine engines," the GRSE official said.

These engines, which are at present imported, are used for fast patrol vessels, interceptor boats and fast attack crafts built by GRSE and other shipyards in the country, he said.

The MoU was signed on Friday by GRSE’s chairman and managing director Commodore (retd) PR Hari and GS Selwyn, managing director of MTU, a solution brand of Power Systems, a fully-owned subsidiary of Rolls Royce, the official added.

Also Read: Harvesting India inks MOU worth $21 million with GRM Overseas; forays into branded agri products

(Edited by : Anushka Sharma)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
Dec 20, 2024
Dec 20 (Reuters) - The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' ( LXRX ) add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday. ...
Credo Technology Group Holding Insider Sold Shares Worth $265,025, According to a Recent SEC Filing
Credo Technology Group Holding Insider Sold Shares Worth $265,025, According to a Recent SEC Filing
Dec 20, 2024
04:42 PM EST, 12/20/2024 (MT Newswires) -- Daniel W. Fleming, Chief Financial Officer, on December 18, 2024, sold 3,790 shares in Credo Technology Group Holding ( CRDO ) for $265,025. Following the Form 4 filing with the SEC, Fleming has control over a total of 652,666 shares of the company, with 652,666 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1807794/000162828024052241/xslF345X05/wk-form4_1734730689.xml ...
Arch Capital Renews $1 Billion Share Repurchase Program
Arch Capital Renews $1 Billion Share Repurchase Program
Dec 20, 2024
04:40 PM EST, 12/20/2024 (MT Newswires) -- Arch Capital Group ( ACGL ) said Friday it has renewed its share repurchase authorization of $1.0 billion, which may be effected from time to time in open market or privately negotiated transactions. The company said the new program replaces its existing buyback authorization. ...
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Dec 20, 2024
Dec 20 - Japanese drugmaker Nippon Shinyaku ( NPNKF ) infringed a Sarepta patent related to its Duchenne muscular dystrophy (DMD) drug Vyondys 53 and must pay $115.2 million in damages, a Delaware jury said on Friday. The jury also rejected competing patent claims by Shinyaku, which had accused Sarepta of violating its patent rights in its DMD drug Viltepso....
Copyright 2023-2026 - www.financetom.com All Rights Reserved